Skip to Main Content

Reunion RE104-203-GAD

About the Study

This study is designed to evaluate the efficacy of 30 mg RE104 on anxiety symptoms compared to placebo.

Participants will receive a single administration of 30 mg RE104 or placebo given as a subcutaneous injection, with preparatory sessions completed prior to dosing and follow-up sessions completed post dosing.

This study is sponsored by Reunion Neuroscience, Inc.

Eligibility

You may be eligible to participate in this study if you:

  • are between the ages of 18 – 74 years old

  • meet DSM-5 criteria for Generalized Anxiety Disorder (GAD)

  • are currently experience symptoms of anxiety

  • can spend the day at our facility for an 8-hour dosing session

  • are willing to delay the initiation or use of any psychotropic and/or pharmacotherapy regimens until the end of the study.

  • have an adult family member or friend who can be available to escort you home at the end of the dosing session

If chosen for this study, you will be compensated for every study visit that you complete and we can provide transportation if needed.

If you are interested in participating in this clinical trial, please call our friendly staff at 773-989-8313 ext. 116 today. You can also fill out the contact form below.